Michael is a 26 year biotech veteran, CEO of Sonescence & SEA Medical Systems, CBO of Strategent, Corium, & Therashock, VP at SciDose & Auspex, & Senior Program Executive at Nektar & Ligand. He raised Seed through Series C and established partnerships worth >$175 Million. Michael led oncology product development including during the Phase III/NDA for Targretin, and business planning for drug delivery of Leuprolide, Paclitaxel and Irinotecan.

Ryan has a diverse background in research, technology commercialization, business development, and financing early stage companies. Ryan provided business planning and company development for many early-stage, technology-based ventures in health-related fields at TEC Edmonton and as an independent consultant. Additionally, he has helped multiple Alberta companies in obtaining financing in his role with the angel investing network, TEC VA.

Luc is a professor of cell biology at University of Alberta with 21 years of experience studying protein fatty acylation. He received his PhD from the Université de Sherbrooke and completed his Post-Doctoral Fellowship at the Memorial Sloan-Kettering Cancer Centre. He has more than 40 publications and 3 patents published or pending. Luc is also the founder and president of Eusera, an antibody manufacturing company in Edmonton, AB.

John is a medical oncologist and Director, Clinical Trials Unit at the Cross Cancer Institute, Professor of Oncology, University of Alberta, and Chair of the Alberta Pre-Phase I Cancer Program (www.prephaseone.com). As Executive Director of Translational Research In Oncology (TRIO), a global clinical trial company, he has access to clinical trial operations and samples to facilitate the clinical evaluation of diagnostic and therapeutic agents.